Abstract A060: Targeting metabolic–DNA repair vulnerabilities in SDHB- and FH-deficient renal cell carcinoma with the novel alkylating agent KL-50
FH- and SDHB-mutant RCC is identified as a molecularly defined subset characterised by epigenetic MGMT silencing, which may confer selective vulnerability to KL-50, which has the potential to overcome resistance mechanisms that have historically constrained the clinical utility of TMZ in this disease context.